

FINANCIAL RELATIONSHIPS WITH INELIGIBLE COMPANIES

In the interest of maintaining the independence of its CME activities and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, course faculty, Scientific Leadership Board, Governance Board, and program staff) to disclose any financial relationships that have had with ineligible companies (previously defined as “commercial interests”) within the previous 24 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered and have been mitigated. Individuals who refuse to disclose financial relationships may not participate in an IAS–USA CME activity. The **ACCME defines ineligible companies** as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.” Below are the financial interests that faculty members of this course have had within the past 24 months. View the [Faculty Financial Disclosure Policy](#).

THE IAS–USA ANNUAL VIRTUAL COURSE UPDATE: EMERGING CHALLENGES IN HIV MEDICINE– DECEMBER 4, 2025

Course Presenters	
Wendy S. Armstrong, MD Professor of Medicine University of Colorado Anschutz Medical Campus Aurora, CO	Dr Armstrong reported no relevant financial relationships with ineligible companies. (Updated November 16, 2025)
Katharine J. Bar, MD Associate Professor of Medicine University of Pennsylvania Philadelphia, PA	Dr Bar reported serving as a consultant for ViiV Healthcare, Merck & Co, Inc, and AbbVie, Inc. (Updated November 11, 2025)
John T. Brooks, MD Co-Editor NIH/HIVMA/IDSA Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV Atlanta, GA	Dr Brooks reported no relevant financial relationships with ineligible companies. (Updated November 11, 2025)
Carolyn Chu, MD, MSc Professor of Clinical Family & Community Medicine University of California San Francisco San Francisco, CA	Dr Chu reported no relevant financial relationships with ineligible companies. (Updated July 25, 2025)
Rajesh T. Gandhi, MD Professor of Medicine Harvard Medical School Massachusetts General Hospital Baltimore, MD	Dr Gandhi reported no relevant financial relationships with ineligible companies. (Updated November 9, 2025)
Khalil G. Ghanem, MD, PhD Professor of Medicine The Johns Hopkins University Baltimore, MD	Dr Ghanem reported no relevant financial relationships with ineligible companies. (Updated November 11, 2025)

IAS–USA CME Planners and Reviewers	
Henry Masur, MD Clinical Professor of Medicine George Washington University Washington, DC	Dr Masur reported no relevant financial relationships with ineligible companies. Updated August 21, 2025)
Michael S. Saag, MD Professor of Medicine University of Alabama at Birmingham Birmingham, AL	Dr Saag reported no relevant financial relationships with ineligible companies. (Updated August 22, 2025)
Donna M. Jacobsen Executive Director/President IAS–USA	Ms Jacobsen reported no relevant financial affiliations with ineligible companies. (Updated November 10, 2025)

IAS–USA Boards

The nonstaff members of the [IAS–USA Scientific Advisory Board](#) and [Governance Board](#) are not compensated for their roles in governing and overseeing the IAS–USA and content development. Please see the About page on the IAS–USA website for information about board members and a link to up-to-date financial disclosure information.

